The lack of an advisory committee meeting reduces regulatory risk and increases approval probability ahead of the PDUFA date. Traders should monitor for any FDA updates and position ahead of the January 2027 decision, especially given the drug's Breakthrough Therapy status and strong Phase 3 data.
PRAX drugs
PRAX drug pipeline →- ▲ relutrigine 8/10 Filed/PDUFA (NDA under priority review) · PDUFA date Dec 27, 2026
- ▲ ulixacaltamide 8/10 Filed/NDA under FDA review (PDUFA January 29, 2027) · PDUFA date Jan 29, 2027
- ● vormatrigine 5/10 Phase 3
- ◆ elsunersen 4/10 Phase 2/3 (registrational)
- ● PRAX-110 4/10
- 4 more · All PRAX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 14 $343.60entry
- T+1 · 7mo ago −1.07%α −1.84% · $339.93
- T+5 · 7mo ago −0.80%α −2.20% · $340.84
- T+20 · 6mo ago −3.43%α −9.73% · $331.81
- T+60 · 4mo ago −3.05%α −11.57% · $333.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Praxis Precision Medicines announced that the FDA has accepted its New Drug Application (NDA) for ulixacaltamide HCl to treat essential tremor, with a PDUFA target action date of January 29, 2027. The FDA does not plan to hold an advisory committee meeting, accelerating the review timeline.
Key Facts
- FDA accepted NDA for ulixacaltamide HCl for essential tremor with PDUFA date of January 29, 2027
- No advisory committee meeting planned, indicating streamlined review process
- NDA supported by positive Phase 3 Essential3 trial results showing statistically and clinically significant efficacy
- Ulixacaltamide received Breakthrough Therapy Designation in December 2025
- Drug was generally well tolerated with no drug-related serious adverse events
Financial Impact
Potential first-in-class therapy for essential tremor, a market with high unmet need; commercial launch preparation underway
Risk Factors
- Regulatory delay or rejection despite PDUFA date
- Commercial execution risk post-approval
- Competition from emerging therapies in CNS space
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3273225 |
Track record
16 reports on PRAX
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jun 29, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $317.69 Now $310.27 +2.34% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $328.13 Now $310.27 −5.44% settles Feb 11
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $332.97 Now $310.27 −6.82% settles Feb 5
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
- Nov 4, 202612d ago Press Release Neutral 1/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $288.62 Now $310.27 +7.50% settles Jan 27
- Jun 29, 202620w ago 8-K Bearish 6/10 Entry $334.79 to $282.12 Now $310.27 +7.32% ▲ +15.73% +18.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $247.98 to $351.81 Now $310.27 +25.12% ▲ +41.87% +37.47% vs SPY
- Jun 2, 202623w ago Press Release Neutral 1/10 Entry $278.93 to $367.85 Now $310.27 +11.24% ▲ +31.88% +29.38% vs SPY
- May 7, 202627w ago Press Release Bullish 8/10 Entry $333.28 to $305.51 Now $310.27 −6.90% ▼ −8.33% −12.17% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers